Free Trial
Dennis Ding

Dennis Ding Analyst Performance

Vice President, Equity Research Analyst at Jefferies Financial Group

Dennis Ding is a stock analyst at Jefferies Financial Group in the medical sector, covering 4 publicly traded companies. Over the past year, Dennis Ding has issued 5 stock ratings, including buy and hold recommendations. While full access to Dennis Ding's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Dennis Ding's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Rankings, Coverage, and Performance Statistics

Average Return
00.00% 12-Month ROI
Success Rate
00.00% Profitable Ratings
Total Ratings
5 Last 0 Years
Buy Recommendations
60.00% 3 Buy Ratings
Companies Covered
4 Unique Companies

Ratings Distribution

RatingPercentageCount
Strong Buy0.0%0 ratings
Buy60.0%3 ratings
Hold40.0%2 ratings
Sell0.0%0 ratings

Out of 5 total stock ratings issued by Dennis Ding at Jefferies Financial Group, the majority (60.0%) have been Buy recommendations, followed by 40.0% Hold.

Best & Worst Calls

This analyst does not have any ratings with enough history to determine best and worst calls.

Exchange Coverage

ExchangePercentageCount
NASDAQ
100.0% of companies on NASDAQ
4 companies

Dennis Ding, an analyst at Jefferies Financial Group, currently covers 4 companies listed on , with the majority traded on NASDAQ.

Coverage Focus

Sector IconSectorPercentage
Medical
4 companies
100.0%

Dennis Ding of Jefferies Financial Group specializes in stock coverage within the Medical sector.

Coverage Industries

IndustryPercentage
MED - BIOMED/GENE
2 companies
50.0%
MED - DRUGS
2 companies
50.0%

Dennis Ding's Ratings History at Jefferies Financial Group

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription
12-Month ROIUpgrade to All Access to use the All ROI Filter
CompanyReport DateActionReport Date Price12-Month
Price Target
Rating12-Month
Price & ROI
Details
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
9/18/2025Boost Price Target$15.17$20.00Buy
Mineralys Therapeutics, Inc. stock logo
MLYS
Mineralys Therapeutics
9/3/2025Boost Price Target$28.86$26.00Hold
Indivior PLC stock logo
INDV
Indivior
7/22/2025Initiated Coverage$15.60$20.00Buy
Mineralys Therapeutics, Inc. stock logo
MLYS
Mineralys Therapeutics
6/10/2025Initiated Coverage$16.03$15.00Hold
Crinetics Pharmaceuticals, Inc. stock logo
CRNX
Crinetics Pharmaceuticals
1/22/2025Upgrade$38.76$55.00Buy